UNSPSC 51372322: Fentanyl hydrochloride

This classification denotes an opioid receptor agonist and opioid with the molecular formula C22H28N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 59H156XY46, chemically known as propionanilide, n-(1-phenethyl-4-piperidyl)-, hydrochloride but more generally known as fentanyl hydrochloride, which bears US NIH Compound Identifier 83932. European Medicines Agency schedules Fentanyl hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21234.

Most nations, for tariff and trade purposes, schedule fentanyl hydrochloride under HS 29333300 and SITC 51574. As of Q4 2014, FENTANYL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Fentanyl hydrochloride bears US NLM identifiers UMLS ID C1714006 and NCI Concept Code C61762. SMILES: CCC(=O)N(C1CCCCC1)C2CCN(CC2)CCC3CCCCC3.CL.

UNSPSC 51372322 Fentanyl hydrochloride, a Commodity code, does not reflect the actual procurement activity currently tagged under it in state and local systems. Recent opportunities posted under this code involve naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products through cooperative purchasing, and direct-to-manufacturer pharmacy prescription programs—none of which are fentanyl itself. The code nominally covers a specific controlled pharmaceutical product, yet issuing bodies are using it to solicit harm-reduction supplies, broad pharmaceutical distribution networks, and pharmacy benefit innovation. This mismatch suggests either systematic miscoding at the source level or misalignment between the UNSPSC taxonomy and current state and local procurement practice for pharmaceutical-category buys.

Issuing bodies posting under this code include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota MMCAP). Recent activity centers in Florida, Texas, and the upper Midwest. Representative opportunities include Seminole County's IFB60459723LAS for 1,900 units of naloxone and 800 safe drug deactivation systems annually (IFB, response deadline July 26, 2023); Texas HHS's RFI HHS0017013 on direct-to-manufacturer prescription program capabilities (RFI, posted April 3, 2026); and Minnesota MMCAP's S1070000015802 for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers (RFP, proposals due March 26, 2026, effective July 1, 2026). The code shows limited relevant recent activity for fentanyl itself and substantial activity in ancillary and broader pharmaceutical procurement categories.